Edition:
United States

Threshold Pharmaceuticals Inc (THLD.O)

THLD.O on Consolidated Issue listed on NASDAQ Capital Market

0.51USD
26 Apr 2017
Change (% chg)

$0.00 (+0.74%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.51
Day's Low
$0.50
Volume
32,546
Avg. Vol
979,139
52-wk High
$1.48
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Threshold Pharmaceuticals posts Q4 loss of $3.7 mln
Monday, 27 Mar 2017 04:01pm EDT 

Threshold Pharmaceuticals Inc : Threshold pharmaceuticals reports fourth quarter and full year 2016 financial results . Threshold pharmaceuticals- no revenue recognized in Q4 and year ended December 31, 2016 compared to $65.9 million and $76.9 million for same periods in 2015 .Threshold pharmaceuticals inc- net loss for Q4 ended December 31, 2016 was $3.7 million compared to net income of $69.7 million for same period in 2015.  Full Article

Threshold Pharmaceuticals and Molecular Templates agree to combine
Friday, 17 Mar 2017 07:17am EDT 

Threshold Pharmaceuticals Inc : Threshold Pharmaceuticals and Molecular Templates agree to combine . Threshold Pharmaceuticals Inc says combined company will be capitalized to support advancement of MT-3724 . Longitude Capital will invest $20 million at close of transaction . Threshold Pharmaceuticals Inc says transaction has been approved by board of directors of both companies . Threshold Pharma - concurrent with execution of merger agreement, Threshold made a bridge loan to Molecular Templates in principal amount of $2 million. . Threshold Pharmaceuticals - Molecular Templates shareholders would own about 65.6 percent of combined company . Threshold - on pro forma basis & based upon number of shares to be issued in deal, current threshold shareholders would own about 34.4 percent of combined co . Threshold Pharmaceuticals - in event that transaction does not close by May 31, 2017, co agreed to make available further funding of up to $2 million . Threshold Pharmaceuticals - Eric Poma, Molecular Templates' chief executive officer, will become Chief Executive Officer of combined company . Threshold Pharmaceuticals - Longitude Capital will invest $20 million including receipt of additional equity financing commitments of $20 million . Threshold Pharmaceuticals - following deal, board of co will consist of seven seats and will be comprised of two representatives of Molecular Templates.  Full Article

First Eagle Investment Management LLC reports 9.91 pct passive stake in Threshold Pharmaceuticals
Monday, 6 Feb 2017 03:31pm EST 

Threshold Pharmaceuticals Inc :First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing.  Full Article

Threshold Pharmaceuticals says to cut about a quarter of its workforce - SEC Filing
Thursday, 29 Sep 2016 05:38pm EDT 

Threshold Pharmaceuticals Inc: Says implementing a workforce reduction constituting approximately a quarter of the company's workforce - SEC Filing . As a result of the workforce reduction, co estimates to record in Q4 a one-time severance-related charge about $0.9 million . Says notified employees affected by the workforce reduction on September 29, 2016 . Says expects to complete the workforce reduction by October 7, 2016 . Threshold pharmaceuticals inc says on September 29, Stewart Kroll, COO, notified that his position would be eliminated as part of workforce reduction .Undertaking workforce reduction to reduce expenses, preserve capital while focusing efforts on studies of Evofosfamide.  Full Article

Threshold Pharmaceuticals Q2 loss per share $0.10
Monday, 1 Aug 2016 08:00am EDT 

Threshold Pharmaceuticals Inc : Q2 revenue $110 million . Threshold Pharmaceuticals reports second quarter financial results . Qtrly loss per share $0.10 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Threshold Pharmaceuticals Inc announces workforce reduction
Friday, 18 Dec 2015 04:17pm EST 

Threshold Pharmaceuticals Inc:Announces workforce reduction.Says will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees.Anticipates one-time severance-related charge associated with workforce reduction to be about $2.6 million.Says the majority of the charges will be paid by the end of the first quarter of 2016.Sees one-time severance-related charge associated with workforce reduction to be about $2.6 million.Enacting reduction in workforce as a result of outcomes from two phase 3 trials of evofosfamide.Says Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA.  Full Article

Threshold Pharmaceuticals Inc - Merck KGaA, Threshold drug fails in late-stage cancer trials - Reuters
Sunday, 6 Dec 2015 10:11pm EST 

Threshold Pharmaceuticals Inc:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals THLD.O said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms - RTRS.Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms. - RTRS.Merck said on Monday it would focus efforts on more promising candidates in its drug pipeline and would soon decide about evofosfamide's overall future - RTRS.The new disappointment leaves CEO-designate Stefan Oschmann, a pharmaceuticals expert, with a narrow drug development pipeline that rests mainly on cancer immune therapy avelumab, jointly developed with Pfizer - RTRS.  Full Article

Threshold Pharmaceuticals Inc enters into definitive co-promotion agreement for evofosfamide with Merck KGaA, Darmstadt, Germany
Wednesday, 18 Nov 2015 07:00am EST 

Threshold Pharmaceuticals Inc:Enters into definitive co-promotion agreement for evofosfamide with Merck KGaA, Darmstadt, Germany.Says may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide.Development milestone payment, royalty payment portions of the license and co-commercialization agreement remain the same.Threshold expects to announce top-line data from evofosfamide phase 3 clinical trials around the end of 2015.  Full Article

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide
Thursday, 27 Aug 2015 07:00am EDT 

Threshold Pharmaceuticals Inc:Announces that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or 'tarloxotinib' (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).  Full Article

More From Around the Web

BRIEF-Threshold Pharmaceuticals posts Q4 loss of $3.7 mln

* Threshold pharmaceuticals reports fourth quarter and full year 2016 financial results